Rare Cell Isolation Market Report 2025

The rare cell isolation market size has grown rapidly in recent years. It will grow from $2.22 billion in 2024 to $2.51 billion in 2025 at a compound annual growth rate (CAGR) of 13%. The growth observed during the historic period can be attributed to the early adoption of cancer research applications, increased investment in academic life science research, initial advancements in immunomagnetic separation, rising demand for prenatal genetic testing, and the emergence of stem cell research in healthcare.

The rare cell isolation market size is expected to see rapid growth in the next few years. It will grow to $4.06 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth during the forecast period can be attributed to a surge in liquid biopsy-based diagnostics, expansion of precision oncology programs, increased analysis of circulating tumor cells, rising demand for non-invasive testing, and growing applications in cell therapy development. Major trends expected in this period include 3D microfluidic isolation systems, gentle isolation techniques to maintain cell viability, integrated downstream analysis platforms, the use of AI and machine learning in rare cell isolation, and the development of point-of-care rare cell isolation devices.

The increasing demand for personalized medicine is expected to drive growth in the rare cell isolation market in the coming years. Personalized medicine is a medical approach that customizes treatment and care based on an individual’s genetic makeup, lifestyle, and environment. This rising demand is fueled by advancements in genomic technologies, which have made genetic testing faster and more cost-effective, enabling healthcare providers to detect specific genetic mutations. Rare cell isolation facilitates personalized medicine by allowing detailed analysis of a patient’s circulating tumor cells, fetal cells, or immune cells, helping clinicians develop treatment plans tailored to the unique molecular and genetic characteristics of these cells. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, up from 6 in 2022. Hence, the growing demand for personalized medicine is propelling the rare cell isolation market forward.

Key players in the rare cell isolation market are concentrating on technological advancements like rare cell and circulating tumor cell enumeration to improve the accuracy, efficiency, and scalability of rare cell detection in cancer diagnostics and personalized medicine. Rare cell and circulating tumor cell enumeration involves identifying and counting rare cells, including cancer cells, in blood or other samples to aid in disease monitoring and research. For instance, in March 2024, Bio-Rad Laboratories, a US-based life sciences company, introduced Celselect Slides Validated Antibodies, an innovative solution for enumerating rare cells and circulating tumor cells. This product features pre-validated antibody panels optimized for use with Celselect Slides, ensuring consistent staining quality and full compatibility with the Celselect platform for rare cell capture. It supports high-content imaging, standardized enumeration, and flexible panel design, enhancing applications in cancer research and liquid biopsy workflows. This advancement simplifies rare cell analysis by reducing assay development time and improving reliability in downstream single-cell analysis workflows.

In July 2022, Bio-Techne Corporation, a US-based biotechnology firm, acquired Namocell, Inc. for an undisclosed amount. This acquisition aims to enhance Bio-Techne’s single-cell analysis and gene therapy workflow solutions by incorporating Namocell’s innovative microfluidic-based single-cell sorting and dispensing technologies into its portfolio. Namocell, Inc., also US-based, specializes in single-cell sorting and dispensing platforms used in rare-cell isolation and cell line development.

Major players in the rare cell isolation market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare Technologies Inc., Corning Incorporated, Lonza Group AG, Terumo BCT Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co KG, Izon Science Limited, RareCyte Inc., Akadeum Life Sciences Inc., NanoCellect Biomedical Inc., CELLENION SASU, Applied Cells Inc.

North America was the largest region in the rare cell isolation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare cell isolation report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the rare cell isolation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare cell isolation market consists of sales of microfluidic devices, immunomagnetic separation kits, dielectrophoretic systems, cell separation reagents and automated rare cell isolation platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

The rare cell isolation market research report is one of a series of new reports that provides rare cell isolation market statistics, including rare cell isolation industry global market size, regional shares, competitors with a rare cell isolation market share, rare cell isolation market segments, market trends and opportunities, and any further data you may need to thrive in the rare cell isolation industry. This rare cell isolation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare cell isolation is the process of separating and enriching specific low-abundance cell populations, such as circulating tumor cells (CTCs) or fetal cells, from a heterogeneous mixture of cells in a sample. This process employs physical, biological, or microfluidic techniques to facilitate the detection, analysis, and characterization of these rare cells for applications in diagnostics, personalized medicine, and research.

The primary products of rare cell isolation include reagents and kits, as well as instruments. Reagents and kits consist of the chemical and biological components used during the rare cell isolation process. These utilize various technologies, such as magnetic bead separation, fluorescence-activated cell sorting, and microfluidics-based methods, and are designed for several cell types, including circulating tumor cells, stem cells, and fetal cells.

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.